Objective: The aims of this study were to evaluate the clinical utility of a fluorescence in situ hybridization (FISH) assay as a non-invasive molecular test to distinguish urothelial carcinoma (UC) in the upper urinary tract (UUT) from benign lesions presenting with hematuria. Study Design: The chromosomal abnormalities of chromosomes 3, 7, 17 and 9 (p16) in hematuria specimens from 34 patients with UUT-UC and 33 patients with benign disorders were detected using a set of fluorescently labeled DNA probes. The abnormalities of the chromosomes were determined and analyzed between UUT-UC and benign disorders. Results: Chromosomal abnormalities were detected in 25 of 34 (73.5%) patients with UUT-UC and in 2 of 33 (6.1%) patients with benign disorders (p < 0.001). Conclusions: FISH of chromosomes 3, 7, 9 and 17 performed on exfoliated cells from voided urine specimens may serve as a non-invasive tool to distinguish UUT-UC from benign disorders presenting with hematuria.

Keywords:
Fluorescence in situ hybridization, Hematuria, Upper urinary tract, Urothelial carcinoma
1.
Chlapoutakis K, Theocharopoulos N, Yarmenitis S, Damilakis J: Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: systematic review and meta-analysis. Eur J Radiol 2010;73:334–338.
2.
Cowan NC: CT urography for hematuria. Nat Rev Urol 2012; 9:218–226.
3.
Rastinehad AR, Ost MC, VanderBrink BA, Siegel DN, Kavoussi LR: Persistent prostatic hematuria. Nat Clin Pract Urol 2008;5:159–165.
4.
Vasdev N, Thorpe AC: Should the presence of a culture positive urinary tract infection exclude patients from rapid evaluation hematuria protocols? Urol Oncol 2011, E-pub ahead of print.
5.
Bubendorf L: Fluorescence in situ hybridization in the diagnosis of urothelial carcinoma. Ann Pathol 2010;30:117–118.
6.
Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J, Manor E: Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Urology 2004;63:398–401.
7.
Halling KC, Kipp BR: Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 2008;15:279–286.
8.
Meloni AM, Peier AM, Haddad FS, Powell IJ, Block AW, Huben RP, Todd I, Potter W, Sandberg AA: A new approach in the diagnosis and follow-up of bladder cancer. FISH analysis of urine, bladder washings, and tumors. Cancer Genet Cytogenet 1993;71:105–118.
9.
Nguyen CT, Litt DB, Dolar SE, Ulchaker JC, Jones JS, Brainard JA: Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer. Urology 2009;73:347–350.
10.
Ratliff TL: Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. J Urol 2005;174:2065.
11.
Cauberg EC, Nio CY, de la Rosette JM, Laguna MP, de Reijke TM: Computed tomography-urography for upper urinary tract imaging: is it required for all patients who present with hematuria? J Endourol 2012;25:1733–1740.
12.
Ko HS, Graf N, Brambs HJ, Debatin KM, Leuschner I, Troger J, Schenk JP: Clinical Quiz. A patient with hematuria and cystic renal mass. Pediatr Nephrol 2006;21:324–327.
13.
Bian Y, Ehya H, Bagley DH: Cytologic diagnosis of upper urinary tract neoplasms by ureteroscopic sampling. Acta Cytol 1995;39:733–740.
14.
Bubendorf L: Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma – FISHing for the right catch. Acta Cytol 2012;55:113–119.
15.
Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL Jr, Zhang HZ, Kamat A, Katz RL: Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol 2011;118:259–268.
16.
Sauter G, Gasser TC, Moch H, Richter J, Jiang F, Albrecht R, Novotny H, Wagner U, Bubendorf L, Mihatsch MJ: DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol Res 1997;25(suppl 1):S37–S43.
17.
Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O’Kane DJ, Seelig SA, Lieber MM, Jenkins RB: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768–1775.
18.
Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W: The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116–123.
19.
Mezzelani A, Dagrada G, Alasio L, Sozzi G, Pilotti S: Detection of bladder cancer by multitarget multicolour FISH: comparative analysis on archival cytology and paraffin-embedded tissue. Cytopathology 2002;13:317–325.
20.
Veeramachaneni R, Nordberg ML, Shi R, Herrera GA, Turbat-Herrera EA: Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 2003;28:301–307.
21.
Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J: Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006;114:279–283.
22.
Reid-Nicholson MD, Ramalingam P, Adeagbo B, Cheng N, Peiper SC, Terris MK: The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder. Mod Pathol 2009;22:119–127.
23.
Johannes JR, Nelson E, Bibbo M, Bagley DH: Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol 2012;184:879–882.
24.
Luo B, Li W, Deng CH, Zheng FF, Sun XZ, Wang DH, Dai YP: Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet Cytogenet 2009;189:93–97.
25.
Marin-Aguilera M, Mengual L, Ribal MJ, Musquera M, Ars E, Villavicencio H, Algaba F, Alcaraz A: Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 2007;51:409–415, discussion 415.
26.
Tapia C, Glatz K, Obermann EC, Grilli B, Barascud A, Herzog M, Schonegg R, Savic S, Bubendorf L: Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. Cancer Cytopathol 2011;119:404–410.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.